NovoCure (NVCR) Return on Capital Employed (2015 - 2026)

NovoCure has disclosed Return on Capital Employed across 12 years of filings, most recently posting 31.69% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 31.69%, up 158.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 31.69% (up 158.0% YoY), and the FY2025 annual result was 19.24%, up 1977.0% from the prior year.
• Return on Capital Employed came in at 31.69% for Q1 2026 at NovoCure, down from 17.89% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 4.43% in Q1 2022 to a low of 35.89% in Q4 2024.
• The 5-year median for Return on Capital Employed is 22.0% (2024), against an average of 21.5%.
• Peak annual rise in Return on Capital Employed reached 1800 bps in 2025, while the deepest fall reached 1617 bps in 2025.
• NovoCure's Return on Capital Employed stood at 8.74% in 2022, then sank by 175 bps to 24.08% in 2023, then slumped by 49 bps to 35.89% in 2024, then jumped by 50 bps to 17.89% in 2025, then tumbled by 77 bps to 31.69% in 2026.
• The last three Return on Capital Employed figures came in at 31.69% (Q1 2026), 17.89% (Q4 2025), and 33.5% (Q3 2025), per Business Quant data.